

Antipsychotic agent (neuroleptic), has antihistaminic, antispasmodic, serotonin-blocking and moderate alpha-blocking effect, as well as antiemetic, hypnotic, sedative and antitussive effect. The antipsychotic action is due to the blockade of the dopamine D2 receptors of the mesolimbic and mesocortical system. Sedative effect due to blockade of adrenergic receptors of the reticular formation of the brain stem; antiemetic action - blockade of the D2 receptors of the trigger zone of the vomiting center; hypothermic action - blockade of dopamine receptors of the hypothalamus. The beginning of the effect - after 15-20 minutes, the duration of action - 6-8 hours.
It has a low antipsychotic activity, therefore it is ineffective in acute psychotic states.
Due to its good tolerance, it is used in pediatric, adolescent and gerontological practice.
Pharmacokinetics:
Quickly and completely absorbed, the maximum concentration in plasma is observed within 1-2 hours after ingestion. Communication with plasma proteins - 20-30%, half-life - 3.5-4 hours. Excreted by the kidneys - 70-80% as a metabolite (sulfoxide) within 48 hours. The beginning of the effect - after 15-20 minutes, the duration of action - 6-8 hours.
Neuroses and neurosis-like states of endogenous and organic genesis with a predominance of senesthopathic, hypochondriac, phobic and psycho-vegetative disorders; psychopathies with asthenic and psychoasthenic disorders; anxiety-depressive states within the framework of endogenous and vascular borderline diseases; senesthopathic depression, somatized mental disorders; states of excitement and anxiety in somatic diseases; sleep disorders of various origins, allergic reactions (symptomatic treatment).
One tablet contains:
Active ingredient: alimemazine tartrate 5 mg
Auxiliary substances: milk sugar (lactose), colloidal silicon dioxide, refined sugar (sucrose), wheat starch, tapioca (tapioca starch), talc, magnesium stearate.
The shell of one tablet contains:
hypromellose, macrogol 6000, titanium dioxide, Osprey R110 pink dye, talc.
No customer reviews for the moment.
Teraligen adminstered orally. The daily dose is divided into 3-4 doses.
Adults - 5–10 mg / day (soporific effect); 60–80 mg / day (anxiolytic effect). In psychotic conditions - 0.2–0.4 g / day.
Children from 7 years old are prescribed according to the following scheme (depending on age and body weight): 2.5–5 mg / day (soporific effect); 5–20 mg / day (as a symptomatic treatment of allergic reactions); 20–40 mg / day (anxiolytic action). In psychotic states, it is possible to increase the daily dose to 60 mg / day.
Teraligen is usually well tolerated. Side effects are extremely rare and not very pronounced.
The nervous system: drowsiness, lethargy, fatigue, occurring mainly in the first days of administration and rarely require discontinuation of the drug; paradoxical reaction (anxiety, agitation, “nightmarish” dreams, irritability); rarely - confusion, extrapyramidal disorders (hypokinesia, akathisia, tremor); increased sleep apnea, increased convulsive activity (in children).
From the senses: blurred vision (paresis of accommodation), noise or tinnitus.
Since the cardiovascular system: dizziness, decrease in blood pressure, tachycardia.
From the digestive system: dry mouth, atony of gastrointestinal tract, constipation, loss of appetite.
On the part of the respiratory system: dry nose, pharynx, increased viscosity of bronchial secretions.
On the part of the urinary system: Atony of the bladder, urinary retention.
Other: allergic reactions, inhibition of bone marrow hematopoiesis, increased sweating, muscle relaxation, photosensitization.
Enhances the effects of narcotic analgesics, hypnotics, anxiolytic (tranquilizers) and antipsychotic drugs (neuroleptics), as well as drugs for general anesthesia, m-holinoblokatorov and hypotensive drugs (dose adjustment is required). Weakens the effect of amphetamine derivatives, m-holino-stimulants, ephedrine, guanetidine, levodopa, dopamine
Ethanol and drugs that inhibit the action of the central nervous system - the oppression of the central nervous system.
Antiepileptic drugs and barbiturates reduce the seizure threshold (dose adjustment is required).
Beta-blockers increase (mutually) plasma concentration (a pronounced decrease in blood pressure, arrhythmias are possible).
Weakens the effect of bromocriptine and increases the concentration of prolactin in the serum.
Tricyclic antidepressants and anticholinergic drugs enhance m-anticholinergic activity.
MAO inhibitors (simultaneous administration is not recommended) and phenothiazine derivatives increase the risk of arterial hypotension and extrapyramidal disorders.
With the simultaneous appointment of alimemazine with drugs that inhibit bone marrow hematopoiesis, the risk of myelosuppression increases.
Hepatotoxic drugs enhance the manifestations of hepatotoxicity of the drug.
With long-term treatment, it is necessary to systematically carry out a complete blood count, evaluate liver function.
It may mask the ototoxic effect (tinnitus and dizziness) of commonly used drugs.
Increases the need for riboflavin.
To prevent the distortion of skin scarification test results for allergens, it is necessary to cancel 72 hours before allergic testing.
During treatment, false positive results for pregnancy are possible.
Against the background of treatment should not engage in activities requiring increased concentration. Alcohol should not be consumed during treatment.
Increased adverse reactions, depression of consciousness.
Treatment - Symptomatic.